More articles from Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Thoracic (Lung/Pleura)

You have access
Radiolabeled PD-L1 targeted nanobody 68Ga-THP-APN09 in predicting the efficacy of neoadjuvant immunotherapy combined chemotherapy in resectable non-small cell lung cancer
Xin Zhou and Nan Li

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 242547;
You have access
[68Ga]Ga-satoreotide trizoxetan uptake in high grade neuroendocrine lung cancers
Tine Christensen, Danijela Dejanovic, Elisabeth Albrecht-Beste, Seppo Langer, Gitte Persson, Jacob Madsen, Nicholas Gillings, Sune Keller and Barbara Fischer

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 242001;
You have access
The role of [18F]FDG PET/CT in pulmonary microwave ablation
Angelo Castello, Paolo Mendogni, Anna Maria Ierardi, Giulia Anna Zuccotti, Florimonte Luigia, Sara Franzi, Alessandro Palleschi, Lorenzo Rosso, Gianpaolo Carrafiello, Davide Tosi and Castellani Massimo

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 242336;
You have access
Value of pre-operative [18F]F-FDG PET/CT in gastroesophageal cancer patientsâ€™ metastatic status prediction and overall survival prognostication: A radiomics study
Seyed Ali Mirshahvalad, Claudia Ortega, Ur Metser, Raymond Jang, Eric Chen, Di Maria Jiang, Jonathan Yeung, Rebecca Wong and Patrick Veit-Haibach

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 242212;
You have access
Comparison of metabolic parameters of Ga-68 FAPI PET/CT and F-18 FDG PET/CT with PD L-1 expression in non-small cell lung cancer
Rajender Kumar, Priyavrat Purohit, Bhagwant Mittal, Harmandeep Singh, Jaya Shukla, Amanjit Bal and Navneet Singh

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 241943;
You have access
18FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal.
Mathilde Masse, David Chardin, Pierre TRICARICO, Nicolas Martin, Jacques Darcourt, Victor Comte and Olivier Humbert

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 242178;
You have access
The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations
Xieraili Wumener, Tao Sun and Ying Liang

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 241787;
You have access
Physiological Uptake of 18F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan
Tomomi Nobashi, Yoichi Shimizu, Kanae Miyake, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Hiroaki Ozasa, Ryo Sakamoto, Jelena Levi and Yuji Nakamoto

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 241532;
You have access
Effects of Significant Hyperglycemia on 18-FDG PET/CT Scan Quality and Accuracy in Patients being Evaluated for Lung Malignancy
Evan Ross and Andrew Ross

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 241773;
You have access
Quantitative 18F-FDG PET/CT for response evaluation after lung ablation for treatment of primary or metastatic lung tumors
Moein Moradpour, Omar Al-Daoud, Sedra Abou Ali Mhana, Thomas Werner, Abass Alavi and Stephen Hunt

Journal of Nuclear Medicine June 1, 2024, 65 (supplement 2) 241588;

Main menu

User menu

Search

More articles from Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Thoracic (Lung/Pleura)

Pages